Qiagen N.V. operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Qiagen N.V. with three other
pharmaceutical manufacturers in Europe:
Krka DD Novo Mesto
sales of 1.16 billion Euro [US$1.27 billion]
of which 64%
was European Union),
Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Reszvenytarsasag
(365.22 billion Hungarian Forints [US$1.29 billion]
of which 82%
was Pharmaceutical Manufacturing and Sale), and
Jazz Pharmaceuticals Plc
based in Ireland
(1.20 billion Euro [US$1.31 billion]
of which 100%
was Pharmaceutical Products).
Qiagen N.V. reported sales of 1.16 billion Euro (US$1.26 billion)
December of 2015.
increase of 14.0%
versus 2014, when the company's sales were 1.02 billion Euro.
Sales at Qiagen N.V. have increased during each of the previous five years
(and since 2010, sales have increased a total of 41%).
Sales of Instrumentation saw an increase
15.8% in 2015, from
130.30 million Euro to 150.87 million Euro.